Artificial Intelligence
Lila Sciences
A Flagship Pioneering-incubated startup building AI-driven 'science factories' -- autonomous, closed-loop research platforms spanning life sciences, chemistry and materials science -- under a stated mission to build 'scientific superintelligence.' Lila Sciences emerged from stealth in March 2025 with $200 million in seed capital, later raised a $350 million Series A, and added a $115 million extension in October 2025 including participation from NVIDIA's venture arm, bringing total funding past $550 million at a valuation exceeding $1.3 billion.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources · 55% avg. source confidence
- Yahoo Finance / Fierce Biotech — Lila Sciences tops $1.3B valuation with NVIDIA-backed extension56% source confidence
- CNBC — Lila Sciences ranks No. 25 on CNBC Disruptor 50, replicates 5-year CAR-T result in 6 months54% source confidence
Dependency Map
What Lila Sciences depends on below, and who depends on Lila Sciences above — click any node to make it the new center, 5 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Lila Sciences's Timeline
A sourced, dated history of Lila Sciences's key moments — founding to present.
Mar 2025 · Emerges from stealth with $200M
Lila Sciences emerged from stealth with $200 million in seed capital to build 'AI science factories' spanning life sciences, chemistry and materials science.
Oct 2025 · Tops $1.3B valuation with NVIDIA-backed extension
Lila Sciences raised a $350 million Series A and a further $115 million extension including NVIDIA's venture arm, bringing total funding past $550 million at a valuation exceeding $1.3 billion.
May 2026 · Ranks No. 25 on CNBC Disruptor 50; replicates 5-year biotech result in 6 months
Lila Sciences ranked No. 25 on CNBC's 2026 Disruptor 50 list; a team of two to three people using Lila's AI Science Factory platform built a complete in vivo CAR-T therapy -- including binder design, mRNA engineering and lipid nanoparticle formulation -- in roughly six months, matching or exceeding results that took biotech Capstan Therapeutics five years and over $100 million using traditional research methods.